SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective respons...

Related Keywords

New York ,United States ,Memorial Sloan Kettering Cancer Center ,Samantha Hilson Sandler ,Saqib Islam ,Jeanne Whiting ,Springworks Careconnections ,Linkedin ,Nasdaq ,Founder Of The Desmoid Tumor Research Foundation ,Drug Administration ,Springworks Therapeutics Inc ,European Medicines Agency ,Desmoid Tumor Working Group ,Youtube ,Exchange Commission ,Us Department Of Commerce ,Twitter ,Media Snippet ,Works Therapeutics ,Chief Executive Officer ,New York City ,New England Journal ,Important Safety Information ,Executive Director Emeritus ,Desmoid Tumor Research ,Marketing Authorisation Application ,Melanoma Skin Cancers ,Embryo Fetal Toxicity ,Acid Reducing Agents ,Prescribing Information ,Springworks Therapeutics ,Private Securities Litigation Reform Act ,Springwork Quarterly Report ,Dei Tos ,Soft Tissue Tumours ,Tumor Working ,Gamma Secretase Inhibitor ,Report Series ,Rare Diseases ,